Don’t Just Say “We’ll Fix It”: FDA Wants Real Investigations in Your 483 Response

In response to what FDA calls “inadequate responses to FDA 483 observations due to a lack or omission of relevant data, excessive amounts of data, and/or failure to address the root cause of observations,” the Agency published a new Draft Guidance on Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection.  The Draft Guidance is applicable to inspections of all foreign and domestic human and animal drug manufacturers, including 503B outsourcing facilities and manufacturers of combination products where CDER or CBER is the lead center.  FDA explains that the Draft Guidance explicitly does not apply to medical devices because the expectation that manufacturers thoroughly investigate unexplained discrepancies is a requirement specific to the drug CGMP regulations (21 CFR 211.192).  However, medical device manufacturers also have a corresponding expectation that they conduct root cause investigations of nonconformities, and as FDA notes in footnote 3, CDRH has a similar expectation described in the Nonbinding Feedback After Certain FDA Inspections of Device Establishments Guidance (April 2020), which we covered previously.

While much of the Draft Guidance documents what are generally industry best practices—particularly those described in ICH Q9 Quality Risk Management and ICH Q10 Pharmaceutical Quality System—there are a few surprises and areas of continuing uncertainty.  Comments on the Draft Guidance can be submitted to Docket FDA-2025-D-1504 through May 8, 2026.

Response Timing

As a reminder, an FDA 483 is issued to a manufacturer during the closeout meeting at the conclusion of an inspection if FDA identifies objectionable conditions or practices that in the investigator’s judgment may constitute violations of the Food, Drug, and Cosmetic Act.  The manufacturer then has 15 business days (excluding weekends and federal holidays) after receiving the FDA 483 to submit a substantive response.  For the purposes of calculating the 15 days, the day the FDA 483 is issued is “day 0.”

The Draft Guidance reiterates FDA’s longstanding position that it will conduct a detailed review of an FDA 483 response submitted within 15 business days before determining whether to take any further action (e.g., issuance of a Warning Letter).  While responding to an FDA 483 is not strictly a legal requirement, we always advise that manufacturers submit a substantive response within the 15-business day timeframe for this reason.  Despite the language in footnote 3, we would not consider this to be a mere “recommendation” as the failure to (or decision not to) respond leaves a manufacturer’s fate wholly in the hands of the Agency.  Similarly, given the importance of the initial FDA 483 response, we recommend that manufacturers take the full 15 business days to prepare a substantive response: there’s no extra credit for responding early.  If all observations have not been completely remediated by the time the initial response is due, which is often the case, manufacturers should provide a list of remediation commitments, timeline for completion of the outstanding commitments, description of interim controls, and the anticipated schedule of response updates.

Format and Content

The Draft Guidance attempts to create a somewhat standardized format for certain portions of the response.  The most significant portion is the Executive Summary table, in which FDA wants to see a detailed description of each observation (or group of related observations) and the status of associated remediation activities.  FDA has provided an example of the Executive Summary table in the Draft Guidance, and we note that this template looks very similar to the Table of Key Elements of a Meeting Package provided in the Post-Warning Letter Meetings Under GDUFA Guidance for Industry.  While many manufacturers already use a similar table format for sections of the response, FDA recommends that the Executive Summary also include the following information for each observation:

1. Patient- and product-focused risk assessment: including an assessment of inventory and distributed drugs still within expiry and any possible effects on safety, identity, strength, quality, and purity of potentially affected drugs.
2. Detailed investigation report: identified root cause(s) of the observation and related systemic issues, list of associated drugs and lot numbers, CAPA plan, summary of completed actions, and planned effectiveness evaluation.
3. Attachments: all should be signed “indicating support for the contents contained therein.” More on the signature recommendation below.

What FDA describes as an “Executive Summary” strikes us as the content for a substantive response in its entirety, but the Draft Guidance states that the “discussion of each FDA 483 observation” is a separate element of the response.  The Draft Guidance also makes clear that investigations initiated in response to the FDA 483 observations need to be comprehensive and not limited to the specific examples cited in the FDA 483.  While it is expected that investigations and CAPAs be extended to other batches, facilities, equipment, personnel, etc., the Draft Guidance specifies that an investigation plan also needs to include a justification for any part of an establishment’s operations that is excluded from the investigation.

Key Takeaways and Outstanding Questions

Overall, while the Draft Guidance provides a recommended format that will presumably make a company’s response easier for FDA to review, the level of detail the Agency expects would be difficult for most manufacturers to prepare by the 15 business day deadline for an initial response.  Beyond the general expectations on format and content, the Draft Guidance has also left us with questions on several specific topics.

1. Discussion items: during an inspection close-out meeting some FDA investigators will discuss what they perceived to be CGMP deficiencies that don’t rise to the level of significance of an FDA 483 observation. These items are noted in the Establishment Inspection Report, but not written on the FDA 483.  In our experience, some firms choose to include a written response to verbal discussion points in their FDA 483 response, others do not.  While the Draft Guidance acknowledges that “Establishments may also provide additional information in their FDA 483 response (e.g., responding to verbal discussion items),” FDA has not provided a clear recommendation on whether manufacturers should reply to discussion points and implications if they do not.
2. Language: if the response includes documents in a foreign language, FDA “does not intend to include these documents in the Agency’s review of the response” unless an English translation is also provided. Additionally, any English translations must be “verified as complete and accurate, with the name address, and brief statement of the translator’s qualifications” [one of the bloggers is a translator by education and she finds this requirement quite interesting].  It is our understanding that, for example, if one of the corrective actions taken in response to an FDA 483 observation were to add a single provision to an existing work instruction, the manufacturer will need to translate the document in its entirety—even if the operating language at the facility is not English and CGMP documentation would not otherwise be maintained in English.
3. Attachments: FDA 483 responses can easily contain dozens, and sometimes hundreds, of attachments. Most, if not all, of these attachments would be CGMP documents (e.g., training records, laboratory reports, SOPs), so it’s unclear why FDA thinks it is necessary for firms to separately sign each attachment.  And it is even less clear why FDA wants its own FDA 483 included as an attachment and sent back to the Agency with the response.
4. Identity of the response preparer: the Draft Guidance says this is required if the response is “not prepared by the establishment.” However, it is ambiguous whether this refers solely to the preparation of the response in its entirety by a third party.  For example, if outside counsel or a CGMP consultant drafts portions of the FDA 483 response, or reviews and revises the response in its entirety, would they be considered the “preparer” of the response?  For larger organizations with multiple sites, corporate Quality personnel may often assist with the preparation of an FDA 483 response for an individual facility, so would they need to be separately identified as a “preparer”?

While the Draft Guidance may not provide absolute certainty around how to respond to an FDA 483, it does stress the importance of submitting a robust response.  HPM attorneys regularly assist drug (and device) manufacturers around the globe with initial FDA 483 responses and response updates, and we can help your company effectively and comprehensively answer FDA’s identified concerns, with the goal of avoiding any further regulatory action.